Cardiocirculatory, biochemical and hemostatic evaluation of dogs with hyperadrenocorticism at diagnosis and after treatment

  • Soares, Frederico Aecio Carvalho (School of Veterinary Medicine, Centro Universitario Ritter dos Reis-UniRitter) ;
  • Matheus, Juliana Pereira (Department of Veterinary Clinical Pathology, School of Veterinary Medicine, Universidade Federal do Rio Grande do Sul) ;
  • Carvalho, Guilherme Luiz (Department of Veterinary Clinical Pathology, School of Veterinary Medicine, Universidade Federal do Rio Grande do Sul) ;
  • Neuwald, Elisa Barp (Department of Veterinary Clinical Pathology, School of Veterinary Medicine, Universidade Federal do Rio Grande do Sul) ;
  • Poppl, Alan Gomes (Department of Veterinary Clinical Pathology, School of Veterinary Medicine, Universidade Federal do Rio Grande do Sul) ;
  • Valle, Stella Faria (Department of Veterinary Clinical Pathology, School of Veterinary Medicine, Universidade Federal do Rio Grande do Sul) ;
  • Gonzalez, Felix Hilario Diaz (Department of Veterinary Clinical Pathology, School of Veterinary Medicine, Universidade Federal do Rio Grande do Sul)
  • Received : 2016.03.14
  • Accepted : 2016.07.11
  • Published : 2016.09.30


Hyperadrenocorticism (HAC) is a common endocrinopathy among dogs that causes multisystemic signs. This study was conducted to evaluate cardiocirculatory, biochemical, and hemostatic parameters in dogs with HAC at diagnosis, in addition to verifying whether abnormal parameters could be controlled by initial treatment with trilostane. Fifteen dogs with HAC were assessed by systolic blood pressure measurement, electrocardiography, Doppler echocardiography, serum concentration of troponin I, and biochemical and hemostatic profile at diagnosis and after trilostane therapy. Unlike biochemical parameters, hemostatic and cardiocirculatory parameters were not significantly influenced by the onset of treatment. The authors believe that clinical treatment with trilostane for 3 to 4 months might not be sufficient for the stabilization of cardiocirculatory abnormalities such as hypertension. Therefore, dogs with HAC must receive cardiocirculatory monitoring at diagnosis and during drug treatment.


  1. Baykan M, Erem C, Gedikli O, Hacihasanoglu A, Erdogan T, Kocak M, Kaplan S, Kiri A, Orem C, Celik S. Assessment of left ventricular diastolic function and Tei index by tissue Doppler imaging in patients with Cushing's syndrome. Echocardiography 2008, 25, 182-190.
  2. Bayram NA, Ersoy R, Aydin C, Gul K, Keles T, Topaloglu O, Durmaz T, Bozkurt E, Cakir B. Assessment of left ventricular functions by tissue Doppler echocardiography in patients with Cushing's disease. J Endocrinol Invest 2009, 32, 248-252.
  3. Behrend EN, Kooistra HS, Nelson R, Reusch CE, Scott-Moncrieff JC. Diagnosis of spontaneous canine hyperadrenocorticism: 2012 ACVIM consensus statement (small animal). J Vet Intern Med 2013, 27, 1292-1304.
  4. Brown S, Atkins C, Bagley R, Carr A, Cowgill L, Davidson M, Egner B, Elliott J, Henik R, Labato M, Littman M, Polzin D, Ross L, Snyder P, Stepien R. Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med 2007, 21, 542-558.
  5. Chen HY, Lien YH, Huang HP. Assessment of left ventricular function by two-dimensional speckle-tracking echocardiography in small breed dogs with hyperadrenocorticism. Acta Vet Scand 2014, 56, 88.
  6. De Leo M, Pivonello R, Auriemma RS, Cozzolino A, Vitale P, Simeoli C, De Martino MC, Lombardi G, Colao A. Cardiovascular disease in Cushing's syndrome: heart versus vasculature. Neuroendocrinology 2010, 92 (Suppl 1), 50-54.
  7. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994, 40, 479-484.
  8. Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filipella M, Di Somma C, Lombardi G, Colao A. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003, 88, 2527-2533.
  9. Fallo F, Maffei P, Dalla Pozza A, Carli M, Della Mea P, Lupia M, Rabbia F, Sonino N. Cardiovascular autonomic function in Cushing's syndrome. J Endocrinol Invest 2009, 32, 41-45.
  10. Fraser R, Davies DL, Connell JMC. Hormones and hypertension. Clin Endocrinol (OXF) 1989, 31, 701-746.
  11. Goy-Thollot I, Pechereau D, Keroack S, Dezempte JC, Bonnet JM. Investigation of the role of aldosterone in hypertension associated with spontaneous pituitary-dependent hyperadrenocorticism. J Small Anim Pract 2002, 43, 489-492.
  12. Helm JR, McLauchlan G, Boden LA, Frowde PE, Collings AJ, Tebb AJ, Elwood CM, Herrtage ME, Parkin TD, Ramsey IK. A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane. J Vet Intern Med 2011, 25, 251-260.
  13. Hurley KJ, Vaden SL. Evaluation of urine protein content in dogs with pituitary-dependent hyperadrenocorticism. J Am Vet Med Assoc 1998, 212, 369-373.
  14. Kamenicky P, Redheuil A, Roux C, Salenave S, Kachenoura N, Raissouni Z, Macron L, Guignat L, Jublanc C, Azarine A, Brailly S, Young J, Mousseaux E, Chanson P. Cardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging study. J Clin Endocrinol Metab 2014, 99, E2144-2153.
  15. Klose TC, Creevy KE, Brainard BM. Evaluation of coagulation status in dogs with naturally occurring canine hyperadrenocorticism. J Vet Emerg Crit Care (San Antonio) 2011, 21, 625-632.
  16. Ljungvall I, Hoglund K, Tidholm A, Olsen LH, Borgarelli M, Venge P, Haggstrom J. Cardiac troponin I associated with severity of myxomatous mitral valve disease, age, and C-reactive protein in dogs. J Vet Intern Med 2010, 24, 153-159.
  17. Magiakou MA, Smyrnaki P, Chrousos GP. Hypertension in Cushing's syndrome. Best Pract Res Clin Endocrinol Metab 2006, 20, 467-482.
  18. Muiesan ML, Lupia M, Salvetti M, Grigoletto C, Sonino N, Boscaro M, Rosei EA, Mantero F, Fallo F. Left ventricular structural and functional characteristics in Cushing's syndrome. J Am Coll Cardiol 2003, 41, 2275-2279.
  19. Nichols R. Atypical Cushing's disease: does it really exist? If so, what is the best treatment? In: 2014 ACVIM Forum Proceedings: In Tune with Innovation & Science, June 4-7, Nashville, 2014.
  20. Novellas R, De Gopegui RR, Espada Y. Determination of renal vascular resistance in dogs with diabetes mellitus and hyperadrenocorticism. Vet Rec 2008, 163, 592-596.
  21. Ortega TM, Feldman EC, Nelson RW, Willits N, Cowgill LD. Systemic arterial blood pressure and urine protein/ creatinine ratio in dogs with hyperadrenocorticism. J Am Vet Med Assoc 1996, 209, 1724-1729.
  22. Oyama MA. Using cardiac biomarkers in veterinary practice. Clin Lab Med 2015, 35, 555-566.
  23. Park FM, Blois SL, Abrams-Ogg ACG, Wood RD, Allen DG, Nykamp SG, Downie A. Hypercoagulability and ACTHdependent hyperadrenocorticism in dogs. J Vet Intern Med 2013, 27, 1136-1142.
  24. Peterson ME. Diagnosis of hyperadrenocorticism in dogs. Clin Tech Small Anim Pract 2007, 22, 2-11.
  25. Pivonello R, De Martino MC, De Leo M, Tauchmanov L, Faggiano A, Lombardi G, Colao A. Cushing's syndrome: aftermath of the cure. Arq Bras Endocrinol Metabol 2007, 51, 1381-1391.
  26. Ramsey IK. Trilostane in dogs. Vet Clin North Am Small Anim Pract 2010, 40, 269-283.
  27. Reine NJ. Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane. Clin Tech Small Anim Pract 2007, 22, 18-25.
  28. Rose L, Dunn ME, Bedard C. Effect of canine hyperadrenocorticism on coagulation parameters. J Vet Intern Med 2013, 27, 207-211.
  29. Schober KE, Cornand C, Kirbach B, Aupperle H, Oechterinag G. Serum cardiac troponin I and cardiac troponin T concentrations in dogs with gastric dilatation-volvulus. J Am Vet Med Assoct 2002, 221, 381-388.
  30. Schober KE, Kirbach B, Oechtering G. Noninvasive assessment of myocardial cell injury in dogs with suspected cardiac contusion. J Vet Cardiol 1999, 1, 17-25.
  31. Sharma ST, Nieman LK. Cushing's syndrome: all variants, detection, and treatment. Endocrinol Metab Clin North Am 2011, 40, 379-391.
  32. Smets PMY, Lefebvre HP, Meij BP, Croubels S, Meyer E, Van de Maele I, Daminet S. Long-term follow-up of renal function in dogs after treatment for ACTH-dependent hyperadrenocorticism. J Vet Intern Med 2012, 26, 565-574.
  33. Tauchmanova L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Palmieri EA, Fazio S, Lombardi G. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 2002, 87, 4872-4878.
  34. Tilley LP. Essentials of Canine and Reline Electrocardiography: Interpretation and Treatment. p. 470, Lea & Febiger, Philadelphia, 1992.
  35. Tilley LP, Smith FWK Jr. Electrocardiography. In: Tilley LP, Smith FWK Jr, Oyama MA, Sleeper MM (eds.). Manual of Canine and Feline Cardiology. 4th ed. pp. 58-65, Saunders, St. Louis, 2008.
  36. Toja PM, Branzi G, Ciambellotti F, Radaelli P, De Martin M, Lonati LM, Scacchi M, Parati G, Cavagnini F, Pecori Giraldi F. Clinical relevance of cardiac structure and function abnormalities in patients with Cushing's syndrome before and after cure. Clin Endocrinol (Oxf) 2012, 76, 332-338.
  37. Torpy DJ, Mullen N, Ilias I, Nieman LK. Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases. Ann N Y Acad Sci 2002, 970, 134-144.
  38. Wess G, Simak J, Mahling M, Hartmann K. Cardiac Troponin I in Doberman Pinschers with cardiomyopathy. J Vet Intern Med 2010, 24, 843-849.
  39. Yiu KH, Marsan NA, Delgado V, Biermasz NR, Holman ER, Smit JW, Feelders RA, Bax JJ, Pereira AM. Increased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome. Eur J Endocrinol 2012, 166, 27-34.